Recent studies have highlighted that an elevated ALT/AST ratio, commonly suggestive of non-alcoholic fatty liver disease (NAFLD), is associated not only with hepatic dysfunction, but also with systemic metabolic disturbances, including insulin resistance and chronic low-grade inflammation (55–58). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.